Complete Genome Sequence of the Edible Filamentous Cyanobacterium Arthrospira platensis NIES-39, Based on Long-Read Sequencing

食用藍藻スピルリナの完全長ゲノム塩基配列 --光合成による有用物質生産の基盤--. 京都大学プレスリリース. 2023-01-20.Arthrospira platensis is a filamentous cyanobacterium that is cultivated and used worldwide as a source of food and food additives. Here, we report the complete genome sequence (6, 818, 916 bp) of A. platensis NIES-39, one of the model strains of A. platensis, providing an improved reference genome sequence for this strain

DDSとしてPICミセルを使用したヒトパピローマウイルス（HPV）癌遺伝子E6およびE7をターゲットとしたsiRNA治療の研究

学位の種別: 課程博士審査委員会委員 : （主査）東京大学教授 本間 之夫, 東京大学準教授 藤代 準, 東京大学准教授 高橋 尚人, 東京大学准教授 岩崎 真一, 東京大学講師 平田 哲也University of Tokyo(東京大学

Enhanced Performance of Sn4P3 Electrode Cycled in Ionic Liquid Electrolyte at Intermediate Temperature as Na‐Ion Battery Anode

Charge-discharge performances of Sn4P3 anodes for Na‐ion battery were evaluated in an ionic liquid electrolyte using N‐methyl‐N‐propylpyrrolidinium bis(fluorosulfonyl)amide at intermediate temperatures of 60 and 90 oC. At these temperatures, the anode showed extra capacities based on the full sodiation of Sn in a potential range below 0.2 V vs. Na+/Na because its slow kinetics was improved by elevating operation temperature. Under the current density of 0.1 A g-1 (0.08 C), the Sn4P3 anode at 60 oC exhibited a large capacity of 750 mA h g-1 at the 120th cycle and high Coulombic efficiencies above 99% after the 5th cycle. On the other hand, the efficiency degraded at 90 oC by the electrolyte decomposition. At 60 oC, the anode attained an excellent rate performance with capacity of 250 mA h g-1 even at 3 A g-1 (2.65 C). These results demonstrated the promising operation at intermediate temperature at around 60 oC for Sn4P3 anode in ionic liquid electrolyte

Electrochemical performance of Sn4P3 negative electrode for Na-ion batteries in ether-substituted ionic liquid electrolyte

We have previously disclosed that the ionic-liquid electrolyte sodium bis(fluorosulfonyl)amide (NaFSA)/1-methyl-1-propylpyrrolidinium bis(fluorosulfonyl)amide (Py13-FSA) can significantly improve the cycling stability of Sn4P3 negative electrodes for Na-ion batteries (NIBs). However, the strong electrostatic interaction between Na+ and FSA− in the electrolyte leads to high viscosity and low conductivity. In this study, we have tried to improve the conductivity of the electrolyte and enhance the rate capability of the Sn4P3 electrode by introducing an ether group in the side-chain of the ionic liquid cation to reduce said electrostatic interaction. Ether-substituted ionic liquid 1-methoxymethyl-1-methylpyrrolidinium (PyMOM)-FSA showed higher conductivity than Py13-FSA and the Sn4P3 electrode exhibited a higher rate capability. The differential capacity vs. potential plots suggest that the reaction between Na+ and Sn or P is promoted in the ether-substituted ionic liquid electrolyte. These results demonstrate that introduction of an ether moiety is an effective approach to improve the rate capability of the Sn4P3 electrode in NIBs

Assessment of a self-assembling peptide gel, SPG-178, in providing a clear operative field for trabeculectomy surgery for glaucoma in an animal model

The presence of blood during ophthalmic surgery is problematic, as it can obstruct a surgeon’s view of the operative field. This is particularly true when performing trabeculectomy surgery to enhance ocular fluid outflow and reduce intraocular pressure as a treatment for glaucoma, one of the most common vision loss conditions worldwide. In this study, we investigated the performance of a transparent, self-assembling peptide gel (SPG-178) and its ability to maintain visibility during trabeculectomy surgery. Unlike the hyaluronic acid gel commonly used in ophthalmic surgery, SPG-178 did not permit the ingress of blood into the gel itself. Rather, it forced blood to flow peripherally to the gel. Moreover, if bleeding occurred under the SPG-178 gel, perfusion with saline was able to effectively flush the blood away along the interface between the SPG-178 and the ocular tissue (in this case scleral) to clear the surgical field of view. In experimental trabeculectomy surgeries with mitomycin C used as an adjuvant, there were no differences in the postoperative recovery of intraocular pressure or bleb morphology with or without the use of SPG-178. SPG-178, therefore, when used in a gel formulation, represents a new material for use in intraocular surgery to ensure a clear operative field with likely beneficial treatment outcomes

Case report: Posterior reversible encephalopathy syndrome, an adverse effect of lenvatinib and pembrolizumab combination therapy, in a patient with advanced endometrial cancer

BackgroundLenvatinib-pembrolizumab combination (LEAP) is an approved therapy in Japan for advanced endometrial cancer, based on the data from the KEYNOTE-775 clinical trial. We report a case of posterior reversible encephalopathy syndrome (PRES) in a patient who received LEAP therapy for advanced endometrial cancer.Case presentationA 53-year-old patient with stage IVB endometrial cancer having rectal metastases, after four cycles of paclitaxel-carboplatin therapy, was found to have increased rectal invasion, peritoneal dissemination, and multiple paraaortic lymph node metastases. She was treated with LEAP therapy and discharged on day 12 without adverse events, except for mild anemia on day 11 of treatment. She was carefully managed in the outpatient department, but on day 18, she was admitted to the emergency department with severely impaired consciousness and generalized seizures. Computed tomography of the head and lumbar tap showed no abnormal findings, and the seizures resolved with anticonvulsant medication alone. Based on a thorough physical examination and findings on magnetic resonance imaging (MRI), which showed high signal intensity in the left occipital lobe, encephalopathy, rather than encephalitis, was the likely diagnosis. Symptomatic improvement was observed, and pembrolizumab monotherapy was resumed.ConclusionsIf consciousness is impaired during LEAP treatment, it is necessary to differentiate between immunogenic encephalitis caused by pembrolizumab or encephalopathy caused by lenvatinib. MRI and lumbar tap can help in distinguishing between the two and diagnosing the responsible drug